MedTrace Logo

Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors

NCT00137774 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2013-04-09

No results posted yet for this study

Summary

The purpose of this study is to determine what effects (good and bad) bevacizumab and temozolomide have on patients with neuroendocrine tumors.

Conditions

Interventions

DRUG

Bevacizumab

Given intravenously every other week. Participants can continue to receive study drug as long as there is no disease progression or serious side effects.

DRUG

Temozolomide

Given once daily for one week followed by a one week rest period. This one-week on/one-week off scheduled will be continued as long as there is no disease progression or serious side effects.

Sponsors & Collaborators

Principal Investigators

  • Matthew H. Kulke, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2005-07-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00137774 on ClinicalTrials.gov